CHEK1 Expression Correlates with Tumor Progression in Lung Adenocarcinoma but Not in Squamous Cell Carcinoma
Open Access
Abstract
Background and Objectives: Non-small cell lung cancer (NSCLC) is histologically divided into adenocarcinoma (AD) and squamous cell carcinoma (SCC). While Checkpoint kinase 1 (CHEK1) regulates the DNA damage response, its subtype-specific clinical impact in NSCLC remains unclear. We investigated the association of CHEK1 expression with clinicopathologic features and prognosis in AD and SCC. Materials and Methods: Transcriptomic and clinical data from 980 patients (492 AD, 488 SCC) were analyzed using The Cancer Genome Atlas (TCGA). Patients were stratified by median CHEK1 mRNA expression. Relationships between expression and clinicopathologic variables were evaluated via Chi-square tests, and overall survival (OS) was assessed using Kaplan–Meier analysis. Results: In AD, high CHEK1 expression significantly correlated with advanced T stage (p < 0.001), lymph node metastasis (p = 0.025), younger age (p = 0.017), and shorter OS (p = 0.025). Conversely, CHEK1 expression in SCC did not reach statistical significance for survival outcomes, although a borderline trend was observed (p = 0.067). Conclusions: CHEK1 is a subtype-specific prognostic biomarker for AD but not for SCC. These findings suggest that CHEK1 overexpression reflects tumor aggressiveness in AD, highlighting its potential as a therapeutic target for this specific population.Keywords
Funding Information
- National Research Foundation of Korea (RS-2025-02305555)
- Korea Health Industry Development Institute
This publication has 33 references indexed in Scilit:
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of CancerCell, 2018
- ATR/CHK1 inhibitors and cancer therapyRadiotherapy and Oncology, 2018
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyThe Lancet Oncology, 2018
- Lung cancer: current therapies and new targeted treatmentsThe Lancet, 2017
- Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung CancerJAMA Oncology, 2016
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non–small cell lung cancerJournal of Surgical Research, 2014
- Roles of Chk1 in cell biology and cancer therapyInternational Journal of Cancer, 2013
- Checkpoint kinase 1 in DNA damage response and cell cycle regulationCellular and Molecular Life Sciences, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011